Table 5 Hazard ratio for all-cause mortality associated with the presence of intra-abdominal cancer in intact AAA patients
All-cause mortality | Crude HR (95% CIs) | Adjusted HR (95% CIs)* | ||||
|---|---|---|---|---|---|---|
Model 1 | Model 2 | |||||
Patients with intact AAA treated by EVAR or OSR (n = 11,785) | ||||||
30-day mortality | 0.82 | (0.47–1.44) | 0.81 | (0.46–1.41) | 0.79 | (0.45–1.38) |
90-day mortality | 0.98 | (0.70–1.36) | 1.18 | (0.97–1.45) | 0.87 | (0.62–1.21) |
Total mortality | 1.41 | (1.25–1.59) | 1.21 | (1.07–1.36) | 1.21 | (1.07–1.37) |
Patients with intact AAA treated by EVAR (n = 7903) | ||||||
30-day mortality | 0.67 | (0.33–1.33) | 0.68 | (0.34–1.36) | 0.66 | (0.33–1.33) |
90-day mortality | 0.86 | (0.59–1.25) | 0.83 | (0.57–1.22) | 0.80 | (0.55–1.18) |
Total mortality | 1.34 | (1.17–1.53) | 1.21 | (1.05–1.38) | 1.21 | (1.05–1.39) |
Patients with intact AAA treated by OSR (n = 3882) | ||||||
30-day mortality | 1.43 | (0.57–3.63) | 1.38 | (0.70–2.73) | 1.28 | (0.50–3.31) |
90-day mortality | 1.39 | (0.72–2.67) | 1.19 | (0.61–2.31) | 1.14 | (0.59–2.22) |
Total mortality | 1.37 | (1.06–1.78) | 1.13 | (0.87–1.47) | 1.16 | (0.89–1.51) |